Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 21, 2025Blood AdvancesOpen Access

Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

TPTycel J. PhillipsMDMengyang DiTMTaavy Miller

Discussion

Loading...

Member takes

Overview

This retrospective cohort study shows improved overall survival with zanubrutinib in adults with mantle cell lymphoma, indicating the importance of treatment selection.

Key Points

  • To evaluate the comparative effectiveness of covalent Bruton tyrosine kinase inhibitors in patients with relapsed/refractory mantle cell lymphoma.
  • Conducted a real-world retrospective cohort study using electronic health records from the US.
  • Included adults with relapsed/refractory mantle cell lymphoma who received second- or third-line monotherapy.
  • Used inverse probability of treatment weighting in adjusted Cox models to analyze time-to-next treatment and overall survival.
  • Among 698 patients, median time-to-next treatment was longest for zanubrutinib at 14.5 months compared to 12.8 months for acalabrutinib and 10.3 months for ibrutinib.
  • Overall survival was median 29.2 months for acalabrutinib and 29.3 months for ibrutinib, with longer survival trends noted for zanubrutinib.
  • Adjustments indicated significantly longer overall survival for zanubrutinib versus ibrutinib, with a hazard ratio of 0.63.

Cite This Study

Phillips et al. (2025) studied this question.

synapsesocial.com/papers/6924e3ecc0ce034ddc34eda9https://doi.org/10.1182/bloodadvances.2025017160
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia2026
  2. 2Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States2026
  3. 3Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma2025 · 1 citations
  4. 4Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting2025 · 2 citations
  5. 5Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma2024 · 5 citations